Moderna
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 5 | 4 | live | 1 | 4 |
| Research labs and data | 5 | 4 | live | 0 | 4 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Moderna scores 5 out of 10 for priority and 4 out of 10 for delivery on both AI in drug discovery and research labs and data, with work in both themes shown live. It describes a Scientific Intelligence Engine that combines data, AI, automation and robotics, with a learning system called Lucy at its centre. Shown running: AI used to design and optimise mRNA constructs at the research stage, a high-throughput line producing up to 1,000 lots of mRNA a month, and a digital portal that tracks materials end to end. In the last 12 months one AI commitment was made public, a University of Alberta AI model for mRNA structure and translation, announced by the university alone; the latest research labs and data commitment, a Benchling platform rollout, came in May 2025, in the year before. On 6 October 2026 Moderna had 4 open R&D roles tied to each theme, including protein design scientists and a digital lab systems engineer, and its sources name lab tools in use such as Benchling, Scitara DLX, Hamilton VENUS, Chromeleon and LabX.
AI in drug discovery
What the company says: Priority 5
Power innovation through our Scientific Intelligence Engine Harness data, AI/ML, automation, and robotics to accelerate discovery and continuously improve how we work
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 116
Our AI strategy turns platform data and biological insight into faster innovation
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 10
Across Moderna, we are building what we call our Scientific Intelligence Engine—a system that combines data, AI and machine learning, automation, and robotics to accelerate discovery and improve how we work.
Building Moderna's Next Decade of Growth (Stephane Bancel, Science Day post), 25 Jun 2026
how we're using AI and robotics to accelerate our ability to discover new technology to expand the use of mRNA to new drug modalities
Q1 2026 Moderna earnings call transcript, 1 May 2026, p. 7
investing in basic science and AI to keep learning and expanding what we can do to help patients
Building Moderna's Next Decade of Growth (Stephane Bancel, Science Day post), 25 Jun 2026
David Huss - Moderna Inc - Chief Technology Officer, Research ... I am responsible for our platform science organization.
Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25
We plan to leverage our global production network, artificial intelligence (AI) and digital tools to improve cost efficiency.
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 9
We expanded the use of AI and digital tools across our teams, helping to improve trial design and data analysis, enhancing forecasting accuracy, reducing waste in our production network
Moderna 2025 Shareholder Letter (Stephane Bancel), 5 Jan 2026
What it shows running: Delivery 4, live
At the research stage, our digital and AI infrastructure allows our scientists to design novel mRNA constructs, use AI algorithms to optimize them and order them from our high throughput preclinical scale production line.
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 26
Lucy is at the heart of Moderna's scientific intelligence engine. Lucy connects everything that we've built in AI, automation, experimentation, and data into a continuously improving learning system.
Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25
We do have an ongoing program to try and improve this algorithm. In fact, we're using artificial intelligence to try to develop the next algorithm.
Q2 2026 Moderna earnings call transcript, 31 Jul 2026, p. 9
multiple integrated algorithms that leverage artificial intelligence and machine learning optimize manufacturability, reduce failures and increase quality of mRNA sequences.
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 24
Commitments made public in the last 12 months: 1
- University of Alberta AI model for mRNA structure and translation: University of Alberta team and Moderna scientists to build an AI-based computational model to improve mRNA medicines. New, announced, 6 Jan 2026. Published by: partner only.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Principal Scientist, Protein Design, Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Scientist, Protein Design, Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Scientist, Therapeutics & Translational Bioinformatics, Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Sr. Research Associate, Protein Design, Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 5
Power innovation through our Scientific Intelligence Engine Harness data, AI/ML, automation, and robotics to accelerate discovery and continuously improve how we work
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 116
Learning at scale requires a fundamentally different experimentation and data infrastructure
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 107
This really requires fundamentally changing the way that we do experimentation and also the data infrastructure that is required to take the data in and make it usable for all of our modern AI tools.
Moderna Science Day transcript (LSEG StreetEvents), 25 Jun 2026, p. 25
Lucy and our digital-first automation platform create the ultimate scientific flywheel, transforming data into intelligence
Moderna Science Day 2026 presentation, 25 Jun 2026, p. 109
What it shows running: Delivery 4, live
High-throughput automation and custom engineered equipment allow us to produce and deliver high quality mRNA and formulated constructs ... our proprietary platform is capable of producing up to 1,000 lots of mRNA sequences and formulations per month
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 24
a series of in vitro based assays and that is what we do within a closed-loop platform ... We've built platforms that allow us to do in vivo multiplex screening in mice and in nonhuman primates.
Moderna Science Day transcript, 25 June 2026, 25 Jun 2026, p. 26
This has been possible, in part, due to the ability of researchers in the Moderna ecosystem to order constructs through an integrated digital portal that tracks materials end-to-end in less than 45 days.
Moderna Form 10-K for fiscal year ended 31 December 2025, 20 Feb 2026, p. 24
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 1
- Benchling R&D digital platform rollout: Benchling release: rollout extended from technical development to Moderna research; expansion will bring hundreds of scientists onto an AI-ready R&D platform. Expanded, in build, 7 May 2025. Published by: partner release, company quoted.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 4
- Integration Lead, Bioassay COE, Norwood, Massachusetts (MTC North - Norwood - USA - MA)
- Principal Systems Engineer, Digital Lab Systems, Norwood, Massachusetts (MTC South - Norwood - USA - MA)
- Sr. Director, Software Engineering, Digital for Research & CMC Development, Cambridge, Massachusetts (325 Binney St - Cambridge - USA - MA)
- Product Manager, Digital for Research and Tech Dev, Norwood, Massachusetts (MTC North - Norwood - USA - MA)
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: Chromeleon, Hamilton, LabX, Scitara DLX, Hamilton liquid handling platforms, Hamilton VENUS, Benchling.
Asked for as experience: SoftMax.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Lab software, lab data and lab automation sit across several units: Digital for Research and CMC Development, a Bioassay centre of excellence, Digital Lab Systems and the product team running Benchling. Who decides on lab software and integration platforms, and how do these units work with the Scientific Intelligence Engine?
- AI for discovery sits in protein design, translational bioinformatics, the Lucy system and a university collaboration, while enterprise AI sits with the Chief People and Digital Technology Officer. Who holds decision rights over discovery AI tools and partners, and how is that spending set while Moderna restructures to cut operating costs?
Coverage limits
The newswire host for Moderna's releases blocked full-text access, so we screened the headline and short summary of every release and read the major events through company PDFs, transcripts and blogs; three releases, including the Harwell centre, were read from summaries only. We could not reach the FY2025 10-K or the 2026 annual report, because SEC EDGAR refused access and the investor site's document host bars automated reading. Fierce Pharma and two other news sites blocked access, and several planned searches, including vendor searches for Benchling, LIMS and lab automation, were not run for lack of search budget. Search coverage is partial, so more activity may exist than is shown here.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call